{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:04:01Z","timestamp":1776978241345,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007631","name":"Chungnam National University Hospital","doi-asserted-by":"crossref","award":["2020"],"award-info":[{"award-number":["2020"]}],"id":[{"id":"10.13039\/501100007631","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bio &amp; Medical Technology Development Program of the National Research Foundation of Korea","award":["NRF-2019M3E5D1A02068550"],"award-info":[{"award-number":["NRF-2019M3E5D1A02068550"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Dasatinib, a tyrosine kinase inhibitor (TKI), induces pulmonary hypertension (PH) in patients with chronic myeloid leukemia (CML). However, information on other TKIs is limited.<\/jats:p>\n            <jats:p>We retrospectively analyzed PH prevalence by reviewing transthoracic echocardiography (TTE) findings in a population of Korean CML patients treated with TKI at a single hospital between 2003 and 2020. PH was defined as a high PH probability according to the European Society of Cardiology\/European Respiratory Society (ESC\/ERS) guidelines.<\/jats:p>\n            <jats:p>Of the 189 patients treated with TKI(s) during the study period, 112 (59.3%) underwent TTE. Among the 112 patients treated with a TKI for a median of 40.4\u200amonths (range: 1.1\u2013167.2\u200amonths), PH was found in 12 (10.7%), most frequently in those treated with dasatinib (ie, in 3 [7.5%] of 40 of those treated with imatinib, 1 [3.1%] of 32 of those treated with nilotinib, and 8 [21.6%] of 37 of those treated with dasatinib). PH resolved in 4 (50.0%) of the 8 dasatinib-treated patients after discontinuation of the agent. One nilotinib-treated and all three imatinib-treated patients recovered from PH. In multivariate analyses, age &gt;60\u200ayears, dasatinib treatment, and positive cardiopulmonary symptoms\/signs at the time of transthoracic echocardiography were statistically significant risk factors for developing PH.<\/jats:p>\n            <jats:p>These results show that PH is induced not only by dasatinib, but also by imatinib and nilotinib. Careful screening for PH during any TKI treatment may thus be warranted in patients with CML.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026975","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T13:02:38Z","timestamp":1629464558000},"page":"e26975","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Pulmonary hypertension in patients with chronic myeloid leukemia"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-970X","authenticated-orcid":false,"given":"Ik-Chan","family":"Song","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hoon","family":"Yeon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyewon","family":"Ryu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwan-Jung","family":"Yun","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Joo","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Hyeong","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ok","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deog-Yeon","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1183\/09031936.00171010","article-title":"Prognosis in pulmonary arterial hypertension","volume":"37","author":"Wensel","year":"2011","journal-title":"Eur Respir J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1111\/j.1742-1241.2007.01479.x","article-title":"Pulmonary hypertension: clinical manifestations, classification and diagnosis","volume":"156","author":"Hegewald","year":"2007","journal-title":"Int J Clin Pract Suppl"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","article-title":"Unexplained pulmonary hypertension in chronic myeloproliferative disorders","volume":"120","author":"Dingli","year":"2001","journal-title":"Chest"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1183\/09031936.00175909","article-title":"Pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"35","author":"Adir","year":"2010","journal-title":"Eur Respir J"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2019.08.004","article-title":"Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients","volume":"68","author":"Venton","year":"2019","journal-title":"Eur J Intern Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.13197","article-title":"Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms","volume":"102","author":"Brabrand","year":"2019","journal-title":"Eur J Haematol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","article-title":"Incremental utility of right ventricular dysfunction in patients with myeloproliferative noplasm-asociated plmonary hpertension","volume":"32","author":"Kim","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5045\/br.2020.2020001","article-title":"Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","article-title":"Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia","volume":"33","author":"Rasheed","year":"2009","journal-title":"Leuk Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.00154210","article-title":"Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia","volume":"38","author":"Dumitrescu","year":"2011","journal-title":"Eur Respir J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.4187\/respcare.02692","article-title":"Reversible pre-capillary pulmonary hypertension due to dasatinib","volume":"59","author":"Buchelli Ramirez","year":"2014","journal-title":"Respir Care"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"937","DOI":"10.4143\/crt.2013.155","article-title":"Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia","volume":"47","author":"Hong","year":"2015","journal-title":"Cancer Res Treat"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.14608","article-title":"Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib","volume":"177","author":"Minami","year":"2017","journal-title":"Br J Haematol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cnardiovascular toxicity in chronic myleoid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clini Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldermeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015\u200aESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e0209148","DOI":"10.1371\/journal.pone.0209148","article-title":"Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: A nationwide study based on the health insurance review and assessment service database","volume":"13","author":"Song","year":"2018","journal-title":"PLoS One"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e0130072","DOI":"10.1371\/journal.pone.0130072","article-title":"Prevalence of pulmonary hypertension in the general population: The Rotterdam Study","volume":"10","author":"Moreira","year":"2015","journal-title":"PLoS One"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxiticy of tyrosine kinase inhibitos used in chronci myelod leukemia: an analysis of the FDA adverse event reporting sysstem database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:00:19Z","timestamp":1746345619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":32,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026975","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"2021-02-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}